Bristol Myers Squibb (NYSE: BMY) announced the expansion of its direct-to-patient drug sales program, offering significant discounts on two prescription ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE